89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate, BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 that is being developed for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
CIKN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees13
Next Earnings DateN/A
OptionableNot Optionable
89bio (NASDAQ:ETNB) Frequently Asked Questions
What is 89bio's stock symbol?
89bio trades on the NASDAQ under the ticker symbol "ETNB."
Has 89bio been receiving favorable news coverage?
Media stories about ETNB stock have been trending somewhat positive on Friday, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. 89bio earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the next several days. View News Stories for 89bio.
Who are some of 89bio's key competitors?
Some companies that are related to 89bio include Vir Biotechnology (VIR), Esperion Therapeutics (ESPR), Sangamo Therapeutics (SGMO), Axsome Therapeutics (AXSM), Brookdale Senior Living (BKD), Innoviva (INVA), Atrion (ATRI), Y-mAbs Therapeutics (YMAB), Arvinas (ARVN), Clinuvel Pharmaceuticals (CUV), National HealthCare (NHC), Alector (ALEC), Coherus Biosciences (CHRS), So-Young International (SY) and Enanta Pharmaceuticals (ENTA).
What other stocks do shareholders of 89bio own?
Who are 89bio's key executives?
89bio's management team includes the folowing people:
- Mr. Rohan Palekar, CEO & Director (Age 53)
- Mr. Ryan Stephen Martins, Chief Financial Officer (Age 42)
- Mr. Ram Waisbourd, COO & Chief Bus. Officer (Age 52)
- Mr. Quoc Le-Nguyen, Chief Technical Operations Officer & Head of Quality (Age 51)
- Dr. Hank Mansbach M.D., Chief Medical Officer (Age 54)
When did 89bio IPO?
(ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.
When does the company's quiet period expire?
89bio's quiet period expires on Monday, December 23rd. 89bio had issued 5,304,687 shares in its IPO on November 11th. The total size of the offering was $84,874,992 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
How do I buy shares of 89bio?
Shares of ETNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is 89bio's stock price today?
One share of ETNB stock can currently be purchased for approximately $28.54.
How big of a company is 89bio?
MarketBeat Community Rating for 89bio (NASDAQ ETNB)
MarketBeat's community ratings are surveys of what our community members think about 89bio and other stocks. Vote "Outperform" if you believe ETNB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ETNB will underperform the S&P 500 over the long term. You may vote once every thirty days.
